500 mg of Flavanols Per Day Causes Cardiovascular Benefits: Real Science, Misleading Precision

The claim is that 500 milligrams of flavanols per day is the scientifically established level for cardiovascular benefit. The verdict is partially false: the number has real scientific grounding, but the precision is misleading and the full picture looks quite different.

The strongest evidence behind the 500 mg figure comes from the COSMOS trial, published in the American Journal of Clinical Nutrition in 2022. This randomized controlled trial followed 21,442 U.S. adults over a median 3.6 years and found that a cocoa extract supplement delivering 500 mg/day of flavanols was associated with a 27% reduction in cardiovascular mortality (HR 0.73, 95% CI 0.54–0.98). That is a large, well-designed trial with a statistically significant hard outcome, and it is the reason the 500 mg figure gained traction. An international expert panel writing in Advances in Nutrition in 2024 (Ottaviani et al.) also cited 500 mg as a central reference point within a recommended range of 400–600 mg/day.

The steelman case for the claim, then, is genuinely strong. But here is precisely where it breaks down: the COSMOS investigators themselves stated that 500 mg was chosen as a practical supplement dose, not derived from a dose-response curve establishing it as the minimum effective level. The trial tested only one dose. You cannot read a threshold off a single-arm comparison.

The broader evidence base makes this clearer. EFSA's 2012 Scientific Opinion — the basis for the only EU-authorized health claim for flavanols — concluded that 200 mg/day is sufficient to contribute to normal endothelium-dependent vasodilation, a recognized cardiovascular surrogate endpoint. Separately, a 2020 Cochrane systematic review of 44 randomized controlled trials found that flavan-3-ols reduced LDL cholesterol and blood pressure at doses ranging from roughly 200 mg to over 1,000 mg/day, with no single dose identified as the minimum effective threshold for hard cardiovascular outcomes. The honest picture is a range, not a number.

It is worth conceding what is genuinely true: 500 mg is not arbitrary. It sits near the center of the expert-recommended range, it is the dose tied to the most compelling mortality data available, and the 2024 expert consensus does use it as a reference point. The problem is not that 500 mg is wrong — it is that presenting it as the validated threshold erases the 200 mg EFSA benchmark, the wide Cochrane dose range, and the fact that COSMOS-Mind found cognitive benefits from 500 mg only in people with low baseline flavanol intake, suggesting the threshold is not universal even within that trial's own data.

The manipulation pattern here is dose laundering: take the specific number used in a high-profile trial, strip away the study design caveat that the dose was chosen pragmatically, and present it as a discovered threshold rather than a tested quantity. Supplement marketers and headline writers are especially prone to this move because a clean number sells. When you see a specific milligram figure cited as the dose for a health benefit, ask two questions: Was a range of doses actually tested? And does a separate regulatory body agree on that number? Here, the answer to both is no.